PubMed:32215613 / 614-770 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T17","span":{"begin":0,"end":14},"obj":"UBERON:0004535"},{"id":"T18","span":{"begin":27,"end":40},"obj":"CHEBI:52217"},{"id":"T19","span":{"begin":27,"end":40},"obj":"CHEBI:52217"},{"id":"T20","span":{"begin":70,"end":74},"obj":"G_3"},{"id":"T21","span":{"begin":70,"end":74},"obj":"PG_10"},{"id":"T22","span":{"begin":70,"end":74},"obj":"PR:000003622"},{"id":"T23","span":{"begin":119,"end":129},"obj":"SP_7"},{"id":"T24","span":{"begin":141,"end":145},"obj":"UBERON:0002048"},{"id":"T25","span":{"begin":150,"end":155},"obj":"UBERON:0000948"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Cardiovascular disease and pharmacologic RAS inhibition both increase ACE2 levels, which may increase the virulence of SARS-CoV-2 within the lung and heart."}

{"project":"LitCovid-OGER","denotations":[{"id":"T1","span":{"begin":106,"end":115},"obj":"GO:0019012"},{"id":"T8","span":{"begin":41,"end":44},"obj":"PR:P03967"},{"id":"T9","span":{"begin":70,"end":74},"obj":"PR:000003622;PR:Q6NKN9"},{"id":"T10","span":{"begin":119,"end":123},"obj":"PR:000014459"},{"id":"T3","span":{"begin":141,"end":145},"obj":"UBERON:0002048"},{"id":"T4","span":{"begin":150,"end":155},"obj":"UBERON:0000948"}],"namespaces":[{"prefix":"PR","uri":"http://purl.obolibrary.org/obo/PR_"},{"prefix":"UBERON","uri":"http://purl.obolibrary.org/obo/UBERON_"}],"text":"Cardiovascular disease and pharmacologic RAS inhibition both increase ACE2 levels, which may increase the virulence of SARS-CoV-2 within the lung and heart."}

{"project":"LitCovid-sentences-v1","denotations":[{"id":"TextSentencer_T5","span":{"begin":0,"end":156},"obj":"Sentence"}],"text":"Cardiovascular disease and pharmacologic RAS inhibition both increase ACE2 levels, which may increase the virulence of SARS-CoV-2 within the lung and heart."}

{"project":"LitCovid-TimeML","denotations":[{"id":"tok99","span":{"begin":0,"end":14},"obj":"NNP"},{"id":"tok100","span":{"begin":15,"end":22},"obj":"NN"},{"id":"tok101","span":{"begin":23,"end":26},"obj":"CC"},{"id":"tok102","span":{"begin":27,"end":40},"obj":"JJ"},{"id":"tok103","span":{"begin":41,"end":44},"obj":"NNP"},{"id":"tok104","span":{"begin":45,"end":55},"obj":"NN"},{"id":"tok105","span":{"begin":56,"end":60},"obj":"DT"},{"id":"tok106","span":{"begin":61,"end":69},"obj":"NN"},{"id":"tok107","span":{"begin":70,"end":73},"obj":"NNP"},{"id":"tok108","span":{"begin":73,"end":74},"obj":"CD"},{"id":"tok109","span":{"begin":75,"end":81},"obj":"NNS"},{"id":"tok110","span":{"begin":81,"end":82},"obj":","},{"id":"tok111","span":{"begin":83,"end":88},"obj":"WDT"},{"id":"tok112","span":{"begin":89,"end":92},"obj":"MD"},{"id":"tok113","span":{"begin":93,"end":101},"obj":"VB"},{"id":"tok114","span":{"begin":102,"end":105},"obj":"DT"},{"id":"tok115","span":{"begin":106,"end":115},"obj":"NN"},{"id":"tok116","span":{"begin":116,"end":118},"obj":"IN"},{"id":"tok117","span":{"begin":119,"end":128},"obj":"NNP"},{"id":"tok118","span":{"begin":128,"end":129},"obj":"CD"},{"id":"tok119","span":{"begin":130,"end":136},"obj":"IN"},{"id":"tok120","span":{"begin":137,"end":140},"obj":"DT"},{"id":"tok121","span":{"begin":141,"end":145},"obj":"NN"},{"id":"tok122","span":{"begin":146,"end":149},"obj":"CC"},{"id":"tok123","span":{"begin":150,"end":155},"obj":"NN"},{"id":"tok124","span":{"begin":155,"end":156},"obj":"."},{"id":"event3","span":{"begin":93,"end":101},"obj":"OCCURRENCE"}],"text":"Cardiovascular disease and pharmacologic RAS inhibition both increase ACE2 levels, which may increase the virulence of SARS-CoV-2 within the lung and heart."}

{"project":"LitCovid-PD-MONDO-v1","denotations":[{"id":"T12","span":{"begin":0,"end":22},"obj":"Disease"},{"id":"T13","span":{"begin":119,"end":127},"obj":"Disease"}],"attributes":[{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Cardiovascular disease and pharmacologic RAS inhibition both increase ACE2 levels, which may increase the virulence of SARS-CoV-2 within the lung and heart."}

{"project":"LitCovid-PD-HP-v1","denotations":[{"id":"T4","span":{"begin":0,"end":22},"obj":"Phenotype"}],"attributes":[{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0001626"}],"text":"Cardiovascular disease and pharmacologic RAS inhibition both increase ACE2 levels, which may increase the virulence of SARS-CoV-2 within the lung and heart."}

{"project":"LitCovid-PD-FMA-UBERON-v1","denotations":[{"id":"T4","span":{"begin":41,"end":44},"obj":"Body_part"},{"id":"T1","span":{"begin":141,"end":145},"obj":"Body_part"},{"id":"T2","span":{"begin":150,"end":155},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A5","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A6","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"}],"text":"Cardiovascular disease and pharmacologic RAS inhibition both increase ACE2 levels, which may increase the virulence of SARS-CoV-2 within the lung and heart."}

{"project":"LitCovid_AGAC","denotations":[{"id":"p118243s7","span":{"begin":61,"end":69},"obj":"PosReg"},{"id":"p118243s8","span":{"begin":70,"end":81},"obj":"MPA"},{"id":"p118243s13","span":{"begin":93,"end":101},"obj":"PosReg"}],"text":"Cardiovascular disease and pharmacologic RAS inhibition both increase ACE2 levels, which may increase the virulence of SARS-CoV-2 within the lung and heart."}